Management of New Consolidation with Pleural Effusion in a Chronic Bronchitis Patient on LABA/ICS

Immediate Management of Acute Pneumonia

The American College of Chest Physicians recommends maintaining the LABA/ICS combination during acute presentations of community-acquired pneumonia, as discontinuing maintenance therapy increases the risk of prolonged recovery time and subsequent exacerbations 1
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines suggest that long-acting bronchodilators provide sustained bronchodilation that remains beneficial even during acute exacerbations and should not be discontinued 1
Initiate appropriate antibiotics for community-acquired pneumonia based on severity and local resistance patterns, and add short-acting bronchodilators for acute symptom relief 1
Consider systemic corticosteroids if there are signs of COPD exacerbation superimposed on the pneumonia 1

The GOLD guidelines note that the patient's current LABA/ICS regimen is not optimal for chronic bronchitis without asthma features, and that ICS therapy is associated with an elevated risk of pneumonia 2, 3, 4, 5
The American Thoracic Society recommends switching to LABA/LAMA and discontinuing ICS for chronic bronchitis patients without asthma features or elevated eosinophils, as LABA/LAMA combinations demonstrate superior efficacy in preventing exacerbations 1, 2, 4, 5
Adding a LAMA to the current LABA/ICS regimen is an option if the patient has features of asthma-COPD overlap or blood eosinophils ≥300 cells/μL 1, 3, 2, 4, 5

The American College of Chest Physicians recommends adding roflumilast if FEV1 <50% predicted and the patient has experienced hospitalization for exacerbation, and adding macrolide therapy if the patient is a former smoker with recurrent exacerbations 3, 2, 4, 5, 6, 1

Do not discontinue long-acting bronchodilators during acute illness, as this worsens outcomes 1
Do not continue ICS indiscriminately in chronic bronchitis patients without asthma features or elevated eosinophils, as this increases pneumonia risk without clear benefit 5, 1
Do not fail to escalate therapy after recovery, as this patient has demonstrated they are at high risk for complications 1, 6